Výsledky vyhledávání

Heart failure with recovered ejection fraction (HFrecEF): A new entity with improved cardiac outcome

Autor: Judith Zeller, Ute Hubauer, Lars S. Maier, Andreas Keyser, Carsten Jungbauer, A L Schober, A D Schober, E Uecer, Sabine Fredersdorf

Background Aim of the study was a better characterization of heart failure (HF) with recovered ejection fraction (HFrecEF) and undulating EF (HFuEF) with regard to re-hospitalization due to congestive HF (CHF), adequate electric therapies (AETs) and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f87ba2642b555a19718fd8089caafc79
https://epub.uni-regensburg.de/50983/

Zobrazit plný text záznamu

Novel Implantable Cardioverter Defibrillator Programming With High Rate Cut-Off, Long Detection Intervals and Multiple Anti-Tachycardia Pacing Reduces Mortality

Autor: A D Schober, A L Schober, Sabine Fredersdorf, Ekrem Ücer, Andreas Keyser, Christoph Birner, Lars S. Maier, Carsten Jungbauer, Joachim Seegers, Ute Hubauer, Stefan Stadler

Publikováno v: Circulation journal : official journal of the Japanese Circulation Society. 85(3)

BACKGROUND Implantable cardioverter defibrillator (ICD) therapies, even when appropriate, are associated with increased risk. Therapy-reducing strategies have been shown to reduce the mortality rate.Methods and Results:In total, 895 patients with ICD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a8ece3fc7753182110d29d9be90a6c9
https://pubmed.ncbi.nlm.nih.gov/33563865

Zobrazit plný text záznamu

Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma

Autor: Arthur Branstrom, Takenobu Nii, Kosei Matsue, Marla Weetall, Yoshiaki Abe, Yuki Nishida, Kensuke Kojima, Shinya Kimura, Wendy D. Schober, Aya Maeda, Liangxian Cao, Mariko Yoshimura, Jo Ishizawa

Publikováno v: Oncotarget

Despite the development of the novel Bruton tyrosine kinase inhibitor ibrutinib, mantle cell lymphoma (MCL) remains an incurable B-cell non-Hodgkin lymphoma. BMI-1 is required for the self-renewal and maintenance of MCL-initiating stem cells. Upregul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d0daedf0502970f5d48323bb973f313
http://europepmc.org/articles/PMC6033370

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

Autor: Xiaorui Zhang, Michael Andreeff, Miguel Gallardo, Huaxian Ma, Peter P. Ruvolo, Wendy D. Schober, Joseph D. Khoury, Ivonne Hernandez, Vivian Ruvolo, Jorge E. Cortes, Sean M. Post, Hong Mu

Publikováno v: Haematologica

Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11bc1b822933cbffd3358968a4da5e84
https://doi.org/10.3324/haematol.2017.168856

Zobrazit plný text záznamu

P2873Novel ICD therapy reduction programming in primary and secondary prevention: reduced mortality and ICD-therapies in a real-life cohort

Autor: Carsten Jungbauer, A D Schober, Stefan Stadler, E Uecer, Lars S. Maier, A L Schober, Ute Hubauer, Sabine Fredersdorf-Hahn, Joachim Seegers

Publikováno v: European Heart Journal. 40

Background Implantable cardioverter defibrillator therapy (ICD), with or without combined cardiac resynchronization therapy, has been demonstrated to reduce mortality and morbidity in patients with heart failure. Nevertheless, ICD therapies are assoc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51ad133bb22ec1f8af34c3aed7fa4a6d
https://doi.org/10.1093/eurheartj/ehz748.1181

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells

Autor: Vivian Ruvolo, Numsen Hail, Michael Andreeff, James Rolke, Ahmed AlRawi, R. Eric Davis, Christopher B. Benton, George F. Tidmarsh, Jared K. Burks, Peter P. Ruvolo, Wendy D. Schober

Publikováno v: Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1863(4):562-571

Galectin 3 (LGALS3) expression is prognostic for poor survival in acute myeloid leukemia (AML) patients. GCS-100 is a novel galectin inhibitor that may prove useful for AML therapy. In this study, we found that GCS-100 induced apoptosis in AML cells.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c97812c81806c2d9d389e25fa37334d

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání